All News

Medicare has not clearly defined what constitutes "established cardiovascular disease," leading to variability in potential patient eligibility; therefore, researchers aimed to estimate the number of Medicare beneficiaries who would become newly eligible for semaglutide under different definitions.

Learn more about the negotiated Medicare drug prices and what the FDA's rejection of therapeutic MDMA means for mental health care through expert reactions. Other highlights include pharmacy-based HIV care, gaps in care for gastrointestinal stromal tumors, and the obesity epidemic.

Disparities in hypertension brought on by neighborhood deprivation were most prominently found in Black patients.

These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations.

The FDA's decision to reject midomafetamine (MDMA) capsules in combination with assisted psychotherapy (MDMA-AT) for adults with PTSD reignited the controversial conversation around investigative psychedelic therapy.

At AIDS 2024 in July, Kelly Dyer, MD, Perelman School of Medicine, presented research findings from an investigation at the intersection of health equity, substance use detox, infectious disease screening, and patient harm reduction.

Adverse outcomes in the aftermath of the COVID-19 pandemic continue to be evaluated as they pertain to social determinants of health, with these authors investigating improvements in food hardship among families participating in the Supplemental Nutrition Assistance Program (SNAP).

Some groups praised CMS after it announced the 10 negotiated Medicare drug prices while others criticized its potential impacts on drug competition and development.

Jennifer Cocohoba, PharmD, MAS, AAHIVP, University of California, San Francisco, School of Pharmacy, discusses the benefits of pharmacy-administered long-acting injectable antiretroviral therapy for HIV and patient attitudes toward pharmacy-administered treatment.

Along with the company reorganization, Lykos announced it will be reducing its workforce by approximately 75%, with the remaining team focused on continuing efforts in clinical development, medical affairs, and engagement with the FDA.

While the evidence demonstrating the poor state of American women's health is not new, the nation's trends of maternal fatality may reflect broader failures in the approach to women's health care.

Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.

Health insurance premiums for 2025 are expected to rise slightly due to higher prescription drug costs and inflation, according to a new analysis from the American Academy of Actuaries.

Andrew Hantel, MD, Dana-Farber Cancer Institute, discusses factors contributing to disparities in oncology clinical trial enrollment.

A trio of posters presented at AIDS 2024, the 25th International AIDS Conference, explored widespread disparities in access to pre-exposure prophylaxis (PrEP) and how to make access more equitable, both globally and locally.

While many states cover routine eye exams, about 6.5 million adults lack comprehensive exam coverage, and around 14.6 million have no access to glasses.

Medicare Advantage (MA) enrollment has grown to 32.8 million in 2024, representing 54% of total Medicare spending, with significant variation in enrollment across states and counties.

For the recent AIDS 2024 conference, we spoke with Nishita Dsouza, PhD, MPH, Columbia University School of Social Work Social Intervention Group, who presented research on HIV and sexually transmitted infection prevention among Black women with criminal legal system involvement.

Medicare Advantage beneficiaries with chronic obstructive pulmonary disease (COPD) who were invited to enroll in a program that reduced inhaler costs and provided medication management had higher inhaler adherence; however, there was no significant impact on exacerbations or overall health care spending.

News surrounding different aspects of health insurance shows changes in weight loss treatment coverage, billing and claims processing errors, and customer service utilization.

Today, the FDA issued a complete response letter (CRL) for midomafetamine capsules (MDMA) in combination with assisted therapy (MDMA-AT) for adults living with posttraumatic stress disorder (PTSD).

A rundown of where Minnesota Gov Tim Walz stands on health policy issues and actions he's taken to improve health care.

The Ochsner-Xavier Institute for Health Equity and Research (OXIHER) is targeting health disparities in Louisiana, focusing on population health management, outcomes research, health careers and equity education, community engagement, and health advocacy and policy.

Chinese adults with a poor socioeconomic status are at a higher risk of developing chronic obstructive pulmonary disease (COPD).

In the second part of our interview with John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council (NPC), he calls for further research into employer choices and the influence of benefit consultants in the pharmacy benefit manager (PBM) and drug rebate landscape.

In part 1 of this interview, Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), explained the research she presented at the 25th International AIDS Conference and the disparities migrant workers continue to encounter in HIV care.

Over 60 bipartisan members of Congress wrote a letter to President Joe Biden stating the urgent need to address the suicide epidemic among veterans, advocating for innovative treatments like therapeutic MDMA.

Minnesota Gov. Tim Walz has been named as Vice President Kamala Harris' Democratic running mate for the 2024 presidential election and has a proven track record in health care reform.

The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still struggling to meet their goals.

John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council, discusses his recent study, which sheds light on how important rebates are when choosing benefits for employers and who advises employers on these choices.